Cantel Medical Corp
Change company Symbol lookup
Select an option...
CMD Cantel Medical Corp
USB U.S. Bancorp
AAPL Apple Inc
AEGN Aegion Corp
AEG Aegon NV
AEE Ameren Corp
AE Adams Resources & Energy Inc
ADXS Advaxis Inc
ADXN Addex Therapeutics Ltd
KO Coca-Cola Co

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company's operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company's Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company's Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Tempur Sealy's stock set to rally after stock split, dividend plans and big profit beat

6:52 am ET October 29, 2020 (MarketWatch)

Shares of Tempur Sealy International Inc. (TPX) were indicated up more than 4% in premarket trading Thursday, after the mattress and bedding maker declared a four-for-1 stock split, said it planned to initiate a dividend and reported a third-quarter profit that was well above expectations. The stock split will go into effect in the fourth quarter of 2020 to make the shares "more accessible to new investors" and improve liquidity; the stock closed Wednesday at $86.90. The company said it also boosted its stock repurchase program by $170 million to $300 million. Separately, net income rose to $121.4 million, or $2.29 a share, from $73.3 million, or $1.31 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share came to $2.94, above the FactSet consensus of $2.20. Sales rose 37.9% to $1.13 billion to beat expectations of $1.07 billion. The company had withdrawn its full-year financial guidance given uncertainties related to the COVID-19 pandemic, but said it expects fourth-quarter sales growth in the low double digits percentage range, while the FactSet sales consensus of $937 million implies a 7.5% rise. The stock has slipped 0.2% year to date through Wednesday, while the S&P 500 has gained 1.3%.

-Tomi Kilgore; 415-439-6400;

(END) Dow Jones Newswires

October 29, 2020 06:52 ET (10:52 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.